Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
CYD-TDV is the first licensed dengue vaccine for individuals 9-45 (or 60) years of age. Using 12% of the subjects enroled in phase-2b and phase-3 trials for which baseline serostatus was measured, the vaccine-induced protection against virologically confirmed dengue during active surveillance (0-25...
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Journal article |
| Publicado: |
Springer Nature
2018
|